Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study
Background - Variation in and irreversibility of platelet inhibition with clopidogrel has led to controversy about its optimum dose and timing of administration in patients with acute coronary syndromes. We compared ticagrelor, a more potent reversible P2Y12 inhibitor with clopidogrel in such patien...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
13 January 2010
|
| In: |
The lancet
Year: 2010, Jahrgang: 375, Heft: 9711, Pages: 283-293 |
| ISSN: | 1474-547X |
| DOI: | 10.1016/S0140-6736(09)62191-7 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/S0140-6736(09)62191-7 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0140673609621917 
|
| Verfasserangaben: | Christopher P Cannon, Robert A Harrington, Stefan James, Diego Ardissino, Richard C Becker, Håkan Emanuelsson, Steen Husted, Hugo Katus, Matyas Keltai, Nardev S Khurmi, Frederic Kontny, Basil S Lewis, Philippe Gabriel Steg, Robert F Storey, Daniel Wojdyla, Lars Wallentin for the PLATelet inhibition and patient Outcomes (PLATO) investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1840460326 | ||
| 003 | DE-627 | ||
| 005 | 20230710144551.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230329s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0140-6736(09)62191-7 |2 doi | |
| 035 | |a (DE-627)1840460326 | ||
| 035 | |a (DE-599)KXP1840460326 | ||
| 035 | |a (OCoLC)1389806857 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Cannon, Christopher P. |e VerfasserIn |0 (DE-588)1121014054 |0 (DE-627)873796039 |0 (DE-576)480654867 |4 aut | |
| 245 | 1 | 0 | |a Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO) |b a randomised double-blind study |c Christopher P Cannon, Robert A Harrington, Stefan James, Diego Ardissino, Richard C Becker, Håkan Emanuelsson, Steen Husted, Hugo Katus, Matyas Keltai, Nardev S Khurmi, Frederic Kontny, Basil S Lewis, Philippe Gabriel Steg, Robert F Storey, Daniel Wojdyla, Lars Wallentin for the PLATelet inhibition and patient Outcomes (PLATO) investigators |
| 264 | 1 | |c 13 January 2010 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.03.2023 | ||
| 520 | |a Background - Variation in and irreversibility of platelet inhibition with clopidogrel has led to controversy about its optimum dose and timing of administration in patients with acute coronary syndromes. We compared ticagrelor, a more potent reversible P2Y12 inhibitor with clopidogrel in such patients. - Methods - At randomisation, an invasive strategy was planned for 13 408 (72·0%) of 18 624 patients hospitalised for acute coronary syndromes (with or without ST elevation). In a double-blind, double-dummy study, patients were randomly assigned in a one-to-one ratio to ticagrelor and placebo (180 mg loading dose followed by 90 mg twice a day), or to clopidogrel and placebo (300-600 mg loading dose or continuation with maintenance dose followed by 75 mg per day) for 6-12 months. All patients were given aspirin. The primary composite endpoint was cardiovascular death, myocardial infarction, or stroke. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00391872. - Findings - 6732 patients were assigned to ticagrelor and 6676 to clopidogrel. The primary composite endpoint occurred in fewer patients in the ticagrelor group than in the clopidogrel group (569 [event rate at 360 days 9·0%] vs 668 [10·7%], hazard ratio 0·84, 95% CI 0·75-0·94; p=0·0025). There was no difference between clopidogrel and ticagrelor groups in the rates of total major bleeding (691 [11·6%] vs 689 [11·5%], 0·99 [0·89-1·10]; p=0·8803) or severe bleeding, as defined according to the Global Use of Strategies To Open occluded coronary arteries, (198 [3·2%] vs 185 [2·9%], 0·91 [0·74-1·12]; p=0·3785). - Interpretation - Ticagrelor seems to be a better option than clopidogrel for patients with acute coronary syndromes for whom an early invasive strategy is planned. - Funding - AstraZeneca. | ||
| 700 | 1 | |a Harrington, Robert A |e VerfasserIn |4 aut | |
| 700 | 1 | |a James, Stefan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ardissino, Diego |e VerfasserIn |4 aut | |
| 700 | 1 | |a Becker, Richard C |e VerfasserIn |4 aut | |
| 700 | 1 | |a Emanuelsson, Håkan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Husted, Steen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Katus, Hugo |d 1951- |e VerfasserIn |0 (DE-588)108916618 |0 (DE-627)577155040 |0 (DE-576)289625076 |4 aut | |
| 700 | 1 | |a Keltai, Matyas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Khurmi, Nardev S |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kontny, Frederic |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lewis, Basil S |e VerfasserIn |4 aut | |
| 700 | 1 | |a Steg, Philippe Gabriel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Storey, Robert F |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wojdyla, Daniel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wallentin, Lars |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet |d London [u.a.] : Elsevier, 1823 |g 375(2010), 9711, Seite 283-293 |h Online-Ressource |w (DE-627)270128484 |w (DE-600)1476593-7 |w (DE-576)078590159 |x 1474-547X |7 nnas |a Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO) a randomised double-blind study |
| 773 | 1 | 8 | |g volume:375 |g year:2010 |g number:9711 |g pages:283-293 |g extent:11 |a Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO) a randomised double-blind study |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S0140-6736(09)62191-7 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0140673609621917 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230329 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 108916618 |a Katus, Hugo |m 108916618:Katus, Hugo |d 910000 |d 910100 |e 910000PK108916618 |e 910100PK108916618 |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 999 | |a KXP-PPN1840460326 |e 4299580060 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"11 S."}],"id":{"doi":["10.1016/S0140-6736(09)62191-7"],"eki":["1840460326"]},"title":[{"title":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO)","subtitle":"a randomised double-blind study","title_sort":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO)"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2010","dateIssuedDisp":"13 January 2010"}],"relHost":[{"title":[{"title":"The lancet","title_sort":"lancet"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["1476593-7"],"eki":["270128484"],"issn":["1474-547X"]},"origin":[{"publisherPlace":"London [u.a.] ; London","dateIssuedKey":"1823","dateIssuedDisp":"1823-","publisher":"Elsevier ; The Lancet Ltd."}],"recId":"270128484","disp":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO) a randomised double-blind studyThe lancet","type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"The lancet <London>"},{"title":"London lancet"},{"title":"Lancet (British ed. Online)"}],"language":["eng"],"part":{"year":"2010","volume":"375","extent":"11","pages":"283-293","issue":"9711","text":"375(2010), 9711, Seite 283-293"},"pubHistory":["1.1823 -"]}],"name":{"displayForm":["Christopher P Cannon, Robert A Harrington, Stefan James, Diego Ardissino, Richard C Becker, Håkan Emanuelsson, Steen Husted, Hugo Katus, Matyas Keltai, Nardev S Khurmi, Frederic Kontny, Basil S Lewis, Philippe Gabriel Steg, Robert F Storey, Daniel Wojdyla, Lars Wallentin for the PLATelet inhibition and patient Outcomes (PLATO) investigators"]},"language":["eng"],"note":["Gesehen am 29.03.2023"],"person":[{"given":"Christopher P.","display":"Cannon, Christopher P.","role":"aut","family":"Cannon"},{"role":"aut","family":"Harrington","given":"Robert A","display":"Harrington, Robert A"},{"display":"James, Stefan","given":"Stefan","family":"James","role":"aut"},{"role":"aut","family":"Ardissino","display":"Ardissino, Diego","given":"Diego"},{"role":"aut","family":"Becker","display":"Becker, Richard C","given":"Richard C"},{"given":"Håkan","display":"Emanuelsson, Håkan","family":"Emanuelsson","role":"aut"},{"given":"Steen","display":"Husted, Steen","family":"Husted","role":"aut"},{"family":"Katus","role":"aut","given":"Hugo","display":"Katus, Hugo"},{"role":"aut","family":"Keltai","display":"Keltai, Matyas","given":"Matyas"},{"given":"Nardev S","display":"Khurmi, Nardev S","family":"Khurmi","role":"aut"},{"family":"Kontny","role":"aut","display":"Kontny, Frederic","given":"Frederic"},{"display":"Lewis, Basil S","given":"Basil S","role":"aut","family":"Lewis"},{"family":"Steg","role":"aut","given":"Philippe Gabriel","display":"Steg, Philippe Gabriel"},{"role":"aut","family":"Storey","display":"Storey, Robert F","given":"Robert F"},{"given":"Daniel","display":"Wojdyla, Daniel","role":"aut","family":"Wojdyla"},{"family":"Wallentin","role":"aut","display":"Wallentin, Lars","given":"Lars"}],"recId":"1840460326"} | ||
| SRT | |a CANNONCHRICOMPARISON1320 | ||